Mepolizumab reduces exacerbations in COPD with type 2 …
Sep 16, 2024 · Adding GSK’s mepolizumab to standard inhaled treatment reduces the frequency of moderate to severe exacerbations in chronic obstructive pulmonary disease (COPD) …
Mepolizumab Significantly Reduces COPD Exacerbations
Sep 12, 2024 · Findings showed a statistically significant and clinically meaningful reduction in the annualized rate of moderate to severe exacerbations with mepolizumab compared with …
Mepolizumab Under Review for Eosinophilic COPD
Dec 11, 2024 · The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic …
Mepolizumab Under Review for Eosinophilic COPD - MPR
Dec 9, 2024 · The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for mepolizumab as an add-on maintenance treatment for chronic …
FDA to review mepolizumab for COPD with eosinophilic …
Dec 11, 2024 · The FDA has accepted to review a supplemental new drug application for mepolizumab, an anti-IL-5 biologic, for treating patients with COPD plus an eosinophilic …
FDA Accepts GSK’s Submission for Use of Mepolizumab in COPD
Dec 9, 2024 · GSK announced today that the US FDA has accepted for review its submission to extend the use of mepolizumab (Nucala) as an add-on maintenance treatment for people with …
Benralizumab versus Mepolizumab for Eosinophilic …
Feb 23, 2024 · Benralizumab, a monoclonal antibody against the interleukin-5α receptor expressed on eosinophils, may be an option for treating EGPA. We conducted a multicenter, …
GSK announces positive results from phase III trial of Nucala ...
Sep 6, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results of MATINEE, the phase III clinical trial evaluating Nucala (mepolizumab), a monoclonal antibody …
Mepolizumab reduces exacerbation rates in patients with COPD
Jul 10, 2024 · SAN DIEGO — Among patients with COPD and heightened eosinophil levels, mepolizumab lowered annualized exacerbation rates, according to a presentation at the …
MATINEE: Mepolizumab Significantly Reduces COPD …
Sep 9, 2024 · Mepolizumab was found to significantly reduce exacerbations in adults with chronic obstructive pulmonary disease (COPD), according to results from the MATINEE trial.